Theravance Biopharma (NASDAQ: TBPH) has announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval for YUPELRI, the company’s revefenacin inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD).
YUPELRI is the first once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of COPD in China.
According to Theravance, the approval initiates a one-time $7.5 million milestone from Viatris (NASDAQ: VTRS) to Theravance, expected to be received in Q3 2025. Theravance is also eligible for additional sales-based milestones of up to $37.5 million, as well as tiered royalties ranging from 14% to 20% on net sales in China. Viatris is responsible for all aspects of YUPELRI’s development and commercialization in China.
